Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDR2-2 in Neovascular Glaucoma
NCT04844619Phase 1Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of KDR2-2 in neovascular glaucoma (NVG) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Changes of iris neovascularization at Day 7. Started Apr 2021; status: active, not recruiting.
02
Drugs
KDR2-2
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT04844619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844619.